SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29: 36518
  • 2
    Oefelein MG, Resnick MI. Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 2003; 62: 20713
  • 3
    Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178 (4 Pt 1): 12905
  • 4
    Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56: 10214
  • 5
    Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2009; 105: 64851
  • 6
    Morote J, Planas J, Salvador C, Raventos CX, Catalan R, Reventos J. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2009; 103: 3325; discussion 335
  • 7
    Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001; 58 (2 Suppl. 1): 59
  • 8
    Koupparis A. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. Commentary. BJU Int 2009; 104: 124; author reply 124–5
  • 9
    Tombal B, Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard®? Eur Urol Suppl 2005; 4: 306
  • 10
    Taieb J, Mathian B, Millot F et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003; 49: 138195
  • 11
    Ludgate CM, Bishop DC, Pai H et al. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation. Int J Radiat Oncol Biol Phys 2005; 62: 130915
  • 12
    Foo M, Lavieri M, Pickles T. Impact of Neo-adjuvant PSA kinetics on biochemical failure and prostate cancer mortality: results from a prospective patient database. American Society of Radiation Oncology Annual Scientific Meeting; 2010; San Diego, CA: International Journal of Radiation Oncology*Biology*Physics. 2010; S362
  • 13
    Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000; 48: 35567
  • 14
    Roach M 3rd, Hanks G, Thames H Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 96574
  • 15
    National_Comprehensive_Cancer_Network. NCCN Clinical Practice Guidelines in Oncology. 2010
  • 16
    Damber J, Tammela T, Abrahamsson P et al. Comparing testosterone and PSA for different baseline testosterone concentrations during initiation of degarelix and leuprolide treatment. Eur Urol Suppl 2009; 8: 130
  • 17
    Koupparis AJ, Tyrrell C. Non-suppression of testosterone in patients with a rising prostatespecific antigen level receiving luteinising hormone-releasing hormone analogues for metastatic prostate cancer. Clin Oncol (R Coll Radiol) 2006; 18: 5712
  • 18
    Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164 (3 Pt 1): 7269
  • 19
    Sharifi R, Browneller R. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 2002; 168: 10014
  • 20
    Smith MR, McGovern FJ. Gonadotropin-releasing hormone agonist failure in a man with prostate cancer. J Urol 2001; 166: 211
  • 21
    Zinner NR, Bidair M, Centeno A, Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized openlabel trial. Urology 2004; 64: 117781
  • 22
    Tombal B, Berges R. Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy. Eur Urol Suppl 2008; 7: 1521
  • 23
    Morote J, Esquena S, Abascal JM et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 2006; 77: 1358
  • 24
    Cabeza A, Gómez A, Vilar S et al. Assessing the incidence of escapes of testosterone in the treatment with LHRH analogs: escape study. ASTRO Annual Scientific Meeting; 2009; Chicago: International Journal of Radiation Oncology, Biology, Physics; 2009; S355
  • 25
    Sartor O, Dineen MK, Perez-Marreno R, Chu FM, Carron GJ, Tyler RC. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology 2003; 62: 31923
  • 26
    Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002; 168: 1199203
  • 27
    Rohl HF, Beuke HP. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 1992; 26: 11- 4
  • 28
    van der Sluis FJ, Heijboer A, Meuleman M et al. Serum concentration of testosterone measured by isotope dilutionliquid Chromatography-tandem mass spectrometry (id-lcms/ ms) in men after bilateral orchiectomy or luteinizing hormone releasing Hormone (lhrh) agonist therapy. Americal urology Association Annual meeting; 2011; Washington, DC.: The Journal of Urology; 2011
  • 29
    Sanofi-aventis. Eligard: Product Monograph, 2010. Available at http://www.sanofi-aventis.ca
  • 30
    Medical_Products_Agency_(Sweden). Bristande kastrationseffekt vid GnRHanalogbehandling (Lack of effect of castration on GnRH analogue treatment). Agency MP ed. 2010
  • 31
    Morote J. Re: Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. Reply to Koupparis BJU Int 104(1) p124. BJU Int 2009; 104: 1245
  • 32
    Crook J, O'Callaghan CJ, Ding K et al. A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013). J Clin Oncol 2011; Supplement ASCO meeting abstracts, Vol 29 issue 15S (part 1 of 2) p2925, abstr# 4514. Chicago; 2011. p. abstr 4514
  • 33
    Hussain M, Tangen CM, Higano C et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 398490
  • 34
    Shore ND, Crawford ED. Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol 2010; 12: 111
  • 35
    Tyrrell CJ, Kaisary AV, Iversen P et al. A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 44756
  • 36
    Iversen P, Tyrrell CJ, Kaisary AV et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51: 38996
  • 37
    Alexander A, Crook J, Jones S et al. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Int J Radiat Oncol Biol Phys 2011; 76: 2330
  • 38
    Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 31020